Comparative study of doramectin and fipronil in the treatment of equine chorioptic mange

D. I. Rendle, H. J. Cottle, S. Love, K. J. Hughes

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


In equids, chorioptic mange is a common dermatitis for which there are no licensed medications in the uk. Doramectin and fipronil are licensed for the control of ectoparasites in other species and were evaluated for the treatment of 17 cases of chorioptic mange in 13 equids. Equids were included if clinical findings were indicative of chorioptic mange, chorioptes mites were positively identified and concurrent disease that could affect response to disease was not evident. A random number table was used to allocate subjects to receive doramectin (group D, eight animals) or fipronil (group F, nine animals). Each of the horses in group D were given 0·3 mg/kg doramectin (Dectomax; Pfizer) on two occasions 14 days apart by subcutaneous injection. All limbs of the horses in group F were sprayed with fipronil 0·25 per cent solution (Frontline; Merial) to the level of the stifles and elbows. Both groups were examined on the day of treatment and 14 and 28 days later to assess the behavioural signs of pruritus and the severity of the dermatological lesions. Acetate tape impressions were collected from the distal limbs and the degree of mite infestation was assessed. By day 28 there were no behavioural signs of chorioptic mange in any of the animals, and there were significant reductions in the numbers of mites in both groups. However, there were no significant reductions in the mean lesion score in either group. There was no significant difference between the effectiveness of the two treatments.
Original languageEnglish
Pages (from-to)335-338
Number of pages4
JournalVeterinary Record
Issue number10
Publication statusPublished - 2007


Dive into the research topics of 'Comparative study of doramectin and fipronil in the treatment of equine chorioptic mange'. Together they form a unique fingerprint.

Cite this